Tonix: Maintaining Buy Rating With Potential Tonmya Expansion Indications (NASDAQ:TNXP)

Group 1 - The article discusses Tonix Pharmaceuticals Holding Corp. (TNXP) and its potential to develop the first new fibromyalgia drug in 15 years [2] - The author, Terry Chrisomalis, has extensive experience in the biotech sector and runs a service that provides in-depth analysis of pharmaceutical companies [2] - The Biotech Analysis Central service includes a library of over 600 biotech investing articles and a model portfolio of small and mid-cap stocks [2] Group 2 - The article does not provide any specific financial data or performance metrics related to Tonix Pharmaceuticals [1][3][4] - There are no disclosures regarding stock positions or plans to initiate positions in the companies mentioned [3] - The article emphasizes that past performance is not indicative of future results, and no investment recommendations are made [4]